Agreement covers cell-based studies, with an additional option to further develop screening activities More: SanegeneBio and Orbit join forces to establish targeting peptides Source: News
read moreSafety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met More: Mission Therapeutics concludes clinical assessment for lead DUB inhibitor Source: News
read moreParticulates, label issues prompt separate recalls for Pfizer’s Hospira and Accord zbecker Wed, 01/04/2023 – 11:35 More: Particulates, label issues prompt separate recalls for Pfizer's Hospira and Accord Source: fierce
read moreAmgen garners wide support from pharma peers in Supreme Court patent fight with Sanofi aliu Wed, 01/04/2023 – 11:12 More: Amgen garners wide support from pharma peers in Supreme Court patent fight with Sanofi Source: fierce
read morePfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report esagonowsky Wed, 01/04/2023 – 10:21 More: Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report Source: fierce
read morePfizer wins—again—in courtroom fight versus Astellas over Lexiscan patents kdunleavy Wed, 01/04/2023 – 10:01 More: Pfizer wins—again—in courtroom fight versus Astellas over Lexiscan patents Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals